The microbial product lipopolysaccharide confers diabetogenic potential on the T cell repertoire of BDC2.5/NOD mice: Implications for the etiology of autoimmune diabetes

Clinical Immunology

Volumn 95, Issue 2, 2000, Pages 93-98

  Balasa, Balaji ^a   Van Gunst, Kurt ^a   Sarvetnick, Nora ^a  

^a SCRIPPS RESEARCH INSTITUTE   (United States)

Author keywords

BDC2.5; Diabetes; Etiology; Infection; Lipopolysaccharide; NOD; Transgenic

Indexed keywords

BACTERIUM LIPOPOLYSACCHARIDE;

ADOPTIVE TRANSFER; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; AUTOIMMUNE DISEASE; B LYMPHOCYTE; CELL ACTIVATION; CELL STIMULATION; CONTROLLED STUDY; DIABETES MELLITUS; DISEASE SEVERITY; INSULITIS; MOUSE; NONHUMAN; PRIORITY JOURNAL; SPLEEN CELL; T LYMPHOCYTE;

EID: 0034127032     PISSN: 15216616     EISSN: None     Source Type: Journal    
DOI: 10.1006/clim.2000.4855     Document Type: Article

References (37)

1. Serreze D. V., Leiter E. H. Genetic and pathogenic basis of autoimmune diabetes in NOD mice. Curr. Opin. Immunol. 6:1994;900-906.
2. Delovitch T. L., Singh B. The nonobese diabetic mouse as a model of autoimmune diabetes: Immune dysregulation gets the NOD. Immunity. 7:1997;727-738.
3. Tisch R., McDevitt H. Insulin-dependent diabtese mellitus. Cell. 85:1996;291-297.
4. Barnett A. H., Eff C., Leslie R. D., Pyke D. A. Diabetes in identical twins. Diabetologia. 20:1981;200-293.
5. Kikutani H., Makino S. The murine autoimmune diabetes model: NOD and related strains. Adv. Immunol. 51:1992;285-322.
6. Rabinovitch A. Immunoregulatory and cytokine imbalances in the pathogenesis of IDDM. Therapeutic intervention by immunostimulation? Diabetes. 43:1994;613-621.
7. Katz J. D., Wang B., Haskins K., Benoist C., Mathis D. Following a diabetogenic T cell from genesis through pathogenesis. Cell. 74:1993;1089-1100.
8. Cavaillon J. M. Cytokines and macrophages. Biomed Pharmacother. 48:1994;445-453.
9. Skeen M. J., Miller M. A., Shinnick T. M., Ziegler H. K. Regulation of murine macrophage IL-12 produciton. Activation of macrophages in vivo, restimulation in vitro, and modulation by other cytokines. J. Immunol. 156:1996;1196-1206.
10. Yoshimoto T., Nagai N., Ohkusu K., Ueda H., Okamura H., Nakanishi K. LPS-stimulated SJL macrophages produce IL-12 and IL-18 that inhibit IgE production in vitro by induction of IFN-gamma production from CD3intIL-2R beta+ T cells. J. Immunol. 161:1998;1483-1492.
11. Zhang X., Sun S., Hwang I., Tough D. F., Sprent J. Potent and selective stimulation of memory-phenotype CD8+ T cells in vivo by IL-15. Immunity. 8:1998;591-599.
12. King C., Sarvetnick N. Organ-specific autoimmunity. Curr. Opin. Immunol. 9:1997;863-871.
13. Lenschow D. J., Ho S. C., Sattar H., Rhee L., Gray G., Nabavi N., Herold K. C., Bluestone J. A. Differential effects of anti-B7-1 and anti-B7-2 monoclonal antibody treatment on the development of diabetes in the nonobese diabetic mouse. J. Exp. Med. 181:1995;1145-1155.
14. Moriyama H., Yokono K., Amano K., Nagata M., Hasegawa Y., Okamoto N., Tsukamoto K., Miki M., Yoneda R., Yagi N., Tominaga Y., Kikutani H., Hioki K., Okumura K., Yagita H., Kasuga M. Induction of tolerance in murine autoimmune diabetes by transient blockade of leukocyte function-associated antigen-1/intercellular adhesion molecule-1 pathway. J. Immunol. 157:1996;3737-3743.
15. Balasa B., Krahl T., Patstone G., Lee J., Tisch R., McDevitt H. O., Sarvetnick N. CD40 ligand-CD40 interacitons are necessary for the initiation of insulitis and diabetes in nonobese diabetic mice. J. Immunol. 159:1997;4620-4627.
16. Hoglund P., Mintern J., Waltzinger C., Heath W., Benoist C., Mathis D. Initiation of autoimmune diabetes by developmentally regulated presentation of islet cell antigens in the pancreatic lymph nodes. J. Exp. Med. 189:1999;331-339.
17. Mueller R., Bradley L. M., Krahl T., Sarvetnick N. Mechanism underlying counterregulation of autoimmune diabetes by IL-4. Immunity. 7:1997;411-418.
18. Horwitz M. S., Bradley L. M., Harbertson J., Krahl T., Lee J., Sarvetnick N. Diabetes induced by Coxsackie virus: initiation by bystander damage and not molecular mimicry. Nat. Med. 4:1998;781-785.
19. Ohashi P. S., Oehen S., Buerki K., Pircher H., Ohashi C. T., Odermatt B., Malissen B., Zinkernagel R. M., Hengartner H. Ablation of "tolerance" and induction of diabetes by virus infection in viral antigen transgenic mice. Cell. 65:1991;305-317.
20. Oldstone M. B., Nerenberg M., Southern P., Price J., Lewiki H. Virus infection triggers insulin-dependent diabetes mellitus in a transgenic model: Role of anti-self (virus) immune response. Cell. 65:1991;319-331.
21. Stewart T. A., Hultgren B., Huang X., Pitts-Meek S., Hully J., MacLachlan N. J. Induction of type 1 diabetes by interferon-alpha in transgenic mice. Science. 260:1993;1942-1946.
22. Ohashi P. S., Oehen S., Aichele P., Pircher H., Odermatt B., Herrera P., Higuchi Y., Buerki K., Hengartner H., Zinkernagel R. M. Induction of diabetes is influenced by the infectious virus and local expression of MHC class 1 and tumor necrosis factor-alpha. J. Immunol. 150:1993;5185-5194.
23. Picarella D. E., Kratz A., LI C. B., Ruddle N. H., Flavell R. A. Transgenic tumor necrosis factor (TNF)-alpha production in pancreatic islets leads to insulitis, not diabetes. J. Immunol. 150:1993;4136-4150.
24. Lee M. S., Mueller R., Wicker L. S., Peterson L. B., Sarvetnick N. IL-10 is necessary and sufficient for autoimmune diabetes in conjunction with NOD MHC homozygosity. J. Exp. Med. 183:1996;2663-2668.
25. Balasa B., Davies J. D., Lee J., Good A., Yeung B. T., Sarvetnick N. IL-10 impacts autoimmune diabetes via a CD8+ T cell pathway circumventing the requirement for CD4+ T and B lymphocytes. J. Immunol. 161:1998;4420-4427.
26. Guerder S., Meyerhoff J., Flavell R. The role of the T cell costimulation B7-1 in autoimmunity and the induction and maintenance of tolerance to peripheral antigen. Immunity. 1:1994;155-166.
27. von Herrath M. G., Guerder S., Lewicki H., Flavell R. A., Oldstone M. B. Coexpression of B7-1 and viral ("self") trangenes in pancreatic beta cells can break peripheral ignorance and lead to spontaneous autoimmune diabetes. Immunity. 3:1995;727-738.
28. Hyoty H., Hiltunen M., Knip M., Laakkonen M., Vahasalo P., Karjalainen J., Koskela P., Roivainen M., Leinikki P., Hovi T. A prospective study of the role of coxsackie B and other enterovirus infections in the pathogenesis of IDDM. Childhood diabetes in Finland (DiMe) study group. Diabetes. 44:1995;652-657.
29. Atkinson M. A., Bowman M. A., Campbell L., Darrow B. L., Kaufman D. L., Maclaren N. K. Cellular immunity to a determinant common to glutamate decarboxylase and coxsackie virus in insulin-dependent diabetes. J. Clin. Invest. 94:1994;2125-2129.
30. Tian J., Lehmann P. V., Kaufman D. L. T cell cross-reactivity between coxsackievirus and glutamate decarboxylase is associated with a murine diabetes susceptibility allele. J. Exp. Med. 180:1994;1979-1984.
31. Segal B. M., Klinman D. M., Shevach E. M. Microbial products induce autoimmune disease by an IL-12-dependent pathway. J. Immunol. 158:1997;5087-5090.
32. Tough D. F., Borrow P., Sprent J. Induction of bystander T cell proliferation by viruses and type 1 interferon in vivo. Science. 272:1996;1947-1950.
33. Tough D. F., Sun S., Sprent J. T cell stimulation in vivo by lipopolysaccharide (LPS). J. Exp. Med. 185:1997;2089-2094.
34. Trembleau S., Penna G., Bosi E., Mortara A., Gately M. K., Adorini L. Interleukin 12 administration induces T helper type 1 cells and accelerates autoimmune diabetes in NOD mice. J. Exp. Med. 181:1995;817-821.
35. Green E. A., Enyaon E. E., Flavell R. A. Local expression of TNFalpha in neonatal NOD mice promotes diabetes by enhancing presentation of islet antigens. Immunity. 9:1998;733-743.
36. Kanegane H., Tosato G. Activation of naive and memory T cells by interleukin-15. Blood. 88:1996;230-235.
37. Griffith T. S., Lynch D. H. TRAIL: A molecule with multiple receptors and control mechanisms. Curr. Opin. Immunol. 10:1998;559-563.